本頁面由Tiger Trade Technology Pte. Ltd.提供服務

Impact Biomedical, Inc.

0.4602
+0.01924.35%
盤後0.46300.0028+0.61%19:59 EDT
成交量:31.06萬
成交額:14.42萬
市值:4,970.16萬
市盈率:65.74
高:0.4900
開:0.4467
低:0.4467
收:0.4410
52周最高:0.8300
52周最低:0.3700
股本:1.08億
流通股本:1,148.81萬
量比:0.33
換手率:2.70%
股息:- -
股息率:- -
每股收益(TTM):0.0070
每股收益(LYR):-0.3800
淨資產收益率:23.46%
總資產收益率:-17.79%
市淨率:4.62
市盈率(LYR):-1.21

資料載入中...

2024/06/11

[修訂]招股説明書

Form S-1/A - General form for registration of securities under the Securities Act of 1933: [Amend]
2024/06/07

重要事件披露

Form 8-K - Current report
2024/05/10

季度報告

Form 10-Q - Quarterly report [Sections 13 or 15(d)]
2024/02/28

[修訂]招股説明書

Form S-1/A - General form for registration of securities under the Securities Act of 1933: [Amend]
2024/02/20

年度報告

Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405]
2024/01/22

重要事件披露

Form 8-K - Current report
2023/11/21

[修訂]招股説明書

Form S-1/A - General form for registration of securities under the Securities Act of 1933: [Amend]
2023/11/13

季度報告

Form 10-Q - Quarterly report [Sections 13 or 15(d)]
2023/11/06

重要事件披露

Form 8-K - Current report
2023/11/01

[修訂]招股説明書

Form S-1/A - General form for registration of securities under the Securities Act of 1933: [Amend]
2023/10/17

招股説明書

Form S-1 - General form for registration of securities under the Securities Act of 1933
2023/10/05

季度報告

Form 10-Q - Quarterly report [Sections 13 or 15(d)]
2023/08/02

SEC問詢函

Form CORRESP - Correspondence
2023/08/01

[修訂]招股説明書

Form S-1/A - General form for registration of securities under the Securities Act of 1933: [Amend]
2023/07/24

[修訂]招股説明書

Form S-1/A - General form for registration of securities under the Securities Act of 1933: [Amend]
2023/07/24

SEC問詢函

Form CORRESP - Correspondence
2023/06/30

[修訂]招股説明書

Form S-1/A - General form for registration of securities under the Securities Act of 1933: [Amend]
2023/06/30

SEC問詢函

Form CORRESP - Correspondence
2023/06/21

[修訂]招股説明書

Form S-1/A - General form for registration of securities under the Securities Act of 1933: [Amend]
2023/06/21

SEC問詢函

Form CORRESP - Correspondence